HUP9900857A2 - T-sejt közvetített autoimmun rendellenességek kezelése - Google Patents
T-sejt közvetített autoimmun rendellenességek kezeléseInfo
- Publication number
- HUP9900857A2 HUP9900857A2 HU9900857A HUP9900857A HUP9900857A2 HU P9900857 A2 HUP9900857 A2 HU P9900857A2 HU 9900857 A HU9900857 A HU 9900857A HU P9900857 A HUP9900857 A HU P9900857A HU P9900857 A2 HUP9900857 A2 HU P9900857A2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- autoimmune disorders
- cell mediated
- mediated autoimmune
- spindle
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A találmány T-sejt felszínén lévő, kőntaktűsfüggő helpereffektőr-fűnkciókat közvetítő receptőr antagőnistájának gyógyszerkészítményekelőállítására történő alkalmazására vőnatkőzik. Ezek agyógyszerkészítmények a szklerózis műltiplex és más T-sejt közvetítettaűtőimműn rendellenességek kezelésére alkalmasak. A találmány szerintalkalmazható kőntaktűsfüggő helpereffektőr-fűnkciókat közvetítőreceptőrantagőnista példáűl egy anti-gp39 antitest. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/481,735 US5833987A (en) | 1995-06-07 | 1995-06-07 | Treatment of T cell mediated autoimmune disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9900857A2 true HUP9900857A2 (hu) | 1999-07-28 |
HUP9900857A3 HUP9900857A3 (en) | 1999-11-29 |
Family
ID=23913182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9900857A HUP9900857A3 (en) | 1995-06-07 | 1996-06-06 | Treatment of t cell mediated autoimmune disorders |
Country Status (17)
Country | Link |
---|---|
US (4) | US5833987A (hu) |
EP (2) | EP0831906B1 (hu) |
JP (1) | JPH11507058A (hu) |
KR (1) | KR100493482B1 (hu) |
CN (2) | CN1827168A (hu) |
AT (1) | ATE214944T1 (hu) |
AU (1) | AU705623B2 (hu) |
CA (1) | CA2223303A1 (hu) |
DE (1) | DE69620174T2 (hu) |
DK (1) | DK0831906T3 (hu) |
ES (1) | ES2177791T3 (hu) |
HU (1) | HUP9900857A3 (hu) |
NO (2) | NO322391B1 (hu) |
NZ (1) | NZ311276A (hu) |
PT (1) | PT831906E (hu) |
WO (1) | WO1996040246A1 (hu) |
ZA (1) | ZA964851B (hu) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
TR199902192T2 (xx) * | 1997-01-10 | 1999-12-21 | Biogen,Inc | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri |
WO1999000143A1 (en) * | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
CN100352497C (zh) * | 1998-04-03 | 2007-12-05 | 达特茅斯学院理事 | 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 |
US20030077667A1 (en) * | 1999-06-01 | 2003-04-24 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
US20070160615A1 (en) * | 1999-06-01 | 2007-07-12 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
US6797263B2 (en) | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
WO2001094586A2 (en) * | 2000-06-06 | 2001-12-13 | Idec Pharmaceuticals Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US20040146949A1 (en) * | 2002-10-25 | 2004-07-29 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
ES2401536T3 (es) * | 2007-11-13 | 2013-04-22 | Evec Inc. | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden |
EP2229914B1 (en) * | 2009-03-20 | 2018-05-30 | Nobel Biocare Services AG | System and method for aligning virtual models |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
KR101614739B1 (ko) * | 2015-12-01 | 2016-04-22 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
MA50435A (fr) | 2017-05-24 | 2020-09-02 | Als Therapy Development Inst | Anticorps anti-ligand anti-cd40 thérapeutiques |
WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US5571507A (en) * | 1992-02-25 | 1996-11-05 | Seragen, Inc. | Methods of treating diabetes |
US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
WO1994028912A1 (en) * | 1993-06-10 | 1994-12-22 | The Regents Of The University Of Michigan | Cd28 pathway immunosuppression |
EP0721346B1 (en) * | 1993-09-02 | 1998-06-10 | Trustees of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
US5565491A (en) * | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
-
1995
- 1995-06-07 US US08/481,735 patent/US5833987A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 ES ES96921309T patent/ES2177791T3/es not_active Expired - Lifetime
- 1996-06-06 HU HU9900857A patent/HUP9900857A3/hu not_active Application Discontinuation
- 1996-06-06 CN CNA2005101286806A patent/CN1827168A/zh active Pending
- 1996-06-06 PT PT96921309T patent/PT831906E/pt unknown
- 1996-06-06 KR KR1019970708752A patent/KR100493482B1/ko not_active IP Right Cessation
- 1996-06-06 CA CA002223303A patent/CA2223303A1/en not_active Abandoned
- 1996-06-06 AU AU62559/96A patent/AU705623B2/en not_active Ceased
- 1996-06-06 WO PCT/US1996/009137 patent/WO1996040246A1/en not_active Application Discontinuation
- 1996-06-06 AT AT96921309T patent/ATE214944T1/de not_active IP Right Cessation
- 1996-06-06 NZ NZ311276A patent/NZ311276A/xx unknown
- 1996-06-06 DK DK96921309T patent/DK0831906T3/da active
- 1996-06-06 CN CN96195877A patent/CN1192156A/zh active Pending
- 1996-06-06 JP JP9501528A patent/JPH11507058A/ja active Pending
- 1996-06-06 DE DE69620174T patent/DE69620174T2/de not_active Expired - Fee Related
- 1996-06-06 EP EP96921309A patent/EP0831906B1/en not_active Expired - Lifetime
- 1996-06-06 EP EP01114411A patent/EP1161954A1/en not_active Withdrawn
- 1996-06-07 ZA ZA964851A patent/ZA964851B/xx unknown
-
1997
- 1997-12-01 NO NO19975520A patent/NO322391B1/no unknown
-
1998
- 1998-05-18 US US09/080,349 patent/US6328964B1/en not_active Expired - Lifetime
-
2001
- 2001-05-08 US US09/849,969 patent/US20020009450A1/en not_active Abandoned
-
2004
- 2004-04-21 US US10/830,310 patent/US20040197327A1/en not_active Abandoned
- 2004-12-15 NO NO20045460A patent/NO20045460L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR19990022273A (ko) | 1999-03-25 |
US20040197327A1 (en) | 2004-10-07 |
AU6255996A (en) | 1996-12-30 |
CN1192156A (zh) | 1998-09-02 |
CN1827168A (zh) | 2006-09-06 |
EP0831906B1 (en) | 2002-03-27 |
US5833987A (en) | 1998-11-10 |
EP0831906A1 (en) | 1998-04-01 |
ATE214944T1 (de) | 2002-04-15 |
ZA964851B (en) | 1997-07-29 |
HUP9900857A3 (en) | 1999-11-29 |
WO1996040246A1 (en) | 1996-12-19 |
AU705623B2 (en) | 1999-05-27 |
NO322391B1 (no) | 2006-10-02 |
NO975520L (no) | 1998-02-06 |
NZ311276A (en) | 1999-11-29 |
CA2223303A1 (en) | 1996-12-19 |
PT831906E (pt) | 2002-09-30 |
ES2177791T3 (es) | 2002-12-16 |
DE69620174D1 (de) | 2002-05-02 |
NO975520D0 (no) | 1997-12-01 |
EP1161954A1 (en) | 2001-12-12 |
DK0831906T3 (da) | 2002-05-21 |
DE69620174T2 (de) | 2002-07-18 |
US20020009450A1 (en) | 2002-01-24 |
JPH11507058A (ja) | 1999-06-22 |
US6328964B1 (en) | 2001-12-11 |
KR100493482B1 (ko) | 2005-08-29 |
NO20045460L (no) | 1998-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9900857A2 (hu) | T-sejt közvetített autoimmun rendellenességek kezelése | |
Zou et al. | Human glioma-induced immunosuppression involves soluble factor (s) that alters monocyte cytokine profile and surface markers | |
NO974258D0 (no) | IL-17-reseptor | |
WO1996030523A3 (en) | Antigen presentation system based on retrovirus-like particles | |
DE69333580D1 (de) | Immunregulation über die cd28-route | |
NL194780B (nl) | Oraal therapeutisch systeem voor toediening van een anticonvulsivum. | |
NO305906B1 (no) | Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler | |
AU6385486A (en) | Sustained release composition | |
AU1380788A (en) | Synthetic peptide antigens for the detection of hiv-1 infection | |
IT1238343B (it) | Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche | |
CA2078549A1 (en) | Multiple sclerosis t-cell receptor | |
ATE208630T1 (de) | Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen | |
AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
AU6819600A (en) | Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections | |
ATE206162T1 (de) | Chemotaktisches protein | |
DK181889D0 (da) | Forbedret fremgangsmaade til omdannelse af ikke-traeagtige lignocellulosesubstrater til produkter til droevtyggere | |
GB9311454D0 (en) | Pharmaceutical compositions | |
NO306113B1 (no) | Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler | |
DE69320364T2 (de) | 6-o-methylguanin-dna-methyltransferase (mgmt) spezifische antikörper | |
Yi et al. | Idiotype-and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes. | |
AR240026A1 (es) | Procedimiento y dispositivo para la separacion de particulas solidasde hidrocarburos clorados liquidos. | |
AU6257486A (en) | Specific mycoplasma membrane antigen and antibody and their clinical applications | |
ITRM910260A0 (it) | Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione | |
AU1875592A (en) | Amino acid sequence of anticancer human monoclonal antibody and dna base sequence coding for the same | |
AU4271693A (en) | Method of detecting expression of T-cell antigen receptor gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC4A | Lapse of provisional application due to refusal |